Effect of Body Composition on Outcomes in Patients with Hepatocellular Carcinoma Undergoing Radiotherapy: A Retrospective Study

References

• Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y
   PubMed Web of Science ®Google Scholar
• Tse RV, Guha C, Dawson LA. Conformal radiotherapy for hepatocellular carcinoma. Crit Rev Oncol Hematol. 2008;67(2):113–123. doi:10.1016/j.critrevonc.2008.01.005
   PubMed Web of Science ®Google Scholar
• Yoon SM, Ryoo B-Y, Lee SJ, Kim JH, Shin JH, An JH, Lee HC, Lim Y-S. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. JAMA Oncol. 2018;4(5):661–669. doi:10.1001/jamaoncol.2017.5847
   PubMed Web of Science ®Google Scholar
• Li L-Q, Zhou Y, Huang Y, Liang P, Liang S-X, Su T-S. Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. Hepatol Int. 2021;15(3):630–641. doi:10.1007/s12072-021-10173-y
   PubMed Web of Science ®Google Scholar
• Hara K, Takeda A, Tsurugai Y, Saigusa Y, Sanuki N, Eriguchi T, Maeda S, Tanaka K, Numata K. Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation: a propensity score analysis. Hepatology. 2019;69:2533–2545. doi:10.1002/hep.30591
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Elsayed Z. External beam radiotherapy for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev. 2017;3:CD011314. doi:10.1002/14651858.CD011314.pub2
   PubMed Web of Science ®Google Scholar
• Lo C-H, Liu M-Y, Lee M-S, Yang J-F, Jen Y-M, Lin C-S, Chao H-L, Shen P-C, Huang W-Y. Comparison between child-turcotte-pugh and albumin-bilirubin scores in assessing the prognosis of hepatocellular carcinoma after stereotactic ablative radiation therapy. Int J Radiat Oncol Biol Phys. 2017;99(1):145–152. doi:10.1016/j.ijrobp.2017.04.036
   PubMed Web of Science ®Google Scholar
• Lo C-H, Lee H-L, Hsiang C-W, Chiou J-F, Lee M-S, Chen S-W, Shen P-C, Lin C-S, Chang W-C, Yang J-F, et al. Pretreatment neutrophil-to-lymphocyte ratio predicts survival and liver toxicity in patients with hepatocellular carcinoma treated with stereotactic ablative radiation therapy. Int J Radiat Oncol Biol Phys. 2021;109(2):474–484. doi:10.1016/j.ijrobp.2020.09.001
   PubMed Web of Science ®Google Scholar
• Huang W-Y, Tsai C-L, Que JY, Lo C-H, Lin Y-J, Dai Y-H, Yang J-F, Shen P-C, Lee M-H, Cheng JC-H, et al. Development and validation of a nomogram for patients with nonmetastatic BCLC stage C hepatocellular carcinoma after stereotactic body radiotherapy. Liver Cancer. 2020;9(3):326–337. doi:10.1159/000505693
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The L, European Organisation For R. Treatment Of C: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943. doi:10.1016/j.jhep.2011.12.001
   PubMed Web of Science ®Google Scholar
• Kapoor ND, Twining PK, Groot OQ, Pielkenrood BJ, Bongers MER, Newman ET, Verlaan JJ, Schwab JH. Adipose tissue density on CT as a prognostic factor in patients with cancer: a systematic review. Acta Oncol. 2020;59(12):1488–1495. doi:10.1080/0284186X.2020.1800087
   PubMed Web of Science ®Google Scholar
• Brown JC, Cespedes Feliciano EM, Caan BJ. The evolution of body composition in oncology-epidemiology, clinical trials, and the future of patient care: facts and numbers. J Cachexia Sarcopenia Muscle. 2018;9(7):1200–1208. doi:10.1002/jcsm.12379
   PubMed Web of Science ®Google Scholar
• Sandini M, Patino M, Ferrone CR, Alvarez-Pérez CA, Honselmann KC, Paiella S, Catania M, Riva L, Tedesco G, Casolino R, et al. Association between changes in body composition and neoadjuvant treatment for pancreatic cancer. JAMA Surg. 2018;153(9):809–815. doi:10.1001/jamasurg.2018.0979
   PubMed Web of Science ®Google Scholar
• Kamarajah SK, Bundred J, Tan BHL. Body composition assessment and sarcopenia in patients with gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2019;22(1):10–22. doi:10.1007/s10120-018-0882-2
   PubMed Web of Science ®Google Scholar
• Labeur TA, van Vugt JLA, Ten Cate DWG, Takkenberg RB, IJzermans JNM, Groot Koerkamp B, de Man RA, van Delden OM, Eskens FALM, Klümpen H-J, et al. Body composition is an independent predictor of outcome in patients with hepatocellular carcinoma treated with sorafenib. Liver Cancer. 2019;8(4):255–270. doi:10.1159/000493586
   PubMed Web of Science ®Google Scholar
• Kobayashi A, Kaido T, Hamaguchi Y, Okumura S, Shirai H, Yao S, Kamo N, Yagi S, Taura K, Okajima H, et al. Impact of sarcopenic obesity on outcomes in patients undergoing hepatectomy for hepatocellular carcinoma. Ann Surg. 2019;269(5):924–931. doi:10.1097/SLA.0000000000002555
   PubMed Web of Science ®Google Scholar
• Benson AB, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D’Angelica MI, Davila R, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009;7(4):350–391. doi:10.6004/jnccn.2009.0027
   PubMed Web of Science ®Google Scholar
• Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629–635. doi:10.1016/S1470-2045(08)70153-0
   PubMed Web of Science ®Google Scholar
• Antoun S, Bayar A, Ileana E, Laplanche A, Fizazi K, di Palma M, Escudier B, Albiges L, Massard C, Loriot Y, et al. High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting. Eur J Cancer. 2015;51(17):2570–2577. doi:10.1016/j.ejca.2015.07.042
   PubMed Web of Science ®Google Scholar
• Imai K, Takai K, Miwa T, Taguchi D, Hanai T, Suetsugu A, Shiraki M, Shimizu M. Rapid depletions of subcutaneous fat mass and skeletal muscle mass predict worse survival in patients with hepatocellular carcinoma treated with sorafenib. Cancers (Basel). 2019;11(8):1206. doi:10.3390/cancers11081206
   PubMed Web of Science ®Google Scholar
• Ebadi M, Martin L, Ghosh S, Field CJ, Lehner R, Baracos VE, Mazurak VC. Subcutaneous adiposity is an independent predictor of mortality in cancer patients. Br J Cancer. 2017;117(1):148–155. doi:10.1038/bjc.2017.149
   PubMed Web of Science ®Google Scholar
• Pai PC, Chuang CC, Chuang WC, Tsang NM, Tseng CK, Chen KH, Yen TC, Lin CY, Chang KP, Lei KF, et al. Pretreatment subcutaneous adipose tissue predicts the outcomes of patients with head and neck cancer receiving definitive radiation and chemoradiation in Taiwan. Cancer Med. 2018;7(5):1630–1641. doi:10.1002/cam4.1365
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Kawai H, Nakano O, Abe S, Kamimura H, Sakamaki A, Kamimura K, Tsuchiya A, Takamura M, Yamagiwa S, et al. Prognostic value of subcutaneous adipose tissue volume in hepatocellular carcinoma treated with transcatheter intra-arterial therapy. CMAR. 2018;10:2231–2239. doi:10.2147/CMAR.S167417
   Web of Science ®Google Scholar
• Imai K, Takai K, Miwa T, Taguchi D, Hanai T, Suetsugu A, Shiraki M, Shimizu M. Rapid depletion of subcutaneous adipose tissue during sorafenib treatment predicts poor survival in patients with hepatocellular carcinoma. Cancers (Basel). 2020;12(7):1795. doi:10.3390/cancers1207
   PubMed Web of Science ®Google Scholar
• Montano-Loza AJ, Mazurak VC, Ebadi M, Meza-Junco J, Sawyer MB, Baracos VE, Kneteman N. Visceral adiposity increases risk for hepatocellular carcinoma in male patients with cirrhosis and recurrence after liver transplant. Hepatology. 2018;67(3):914–923. doi:10.1002/hep.29578
   PubMed Web of Science ®Google Scholar
• Hessen L, Roumet M, Maurer MH, Lange N, Reeves H, Dufour J‐F, Radu P. High subcutaneous adipose tissue density correlates negatively with survival in patients with hepatocellular carcinoma. Liver Int. 2021;41(4):828–836. doi:10.1111/liv.14755
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–73e1. doi:10.1053/j.gastro.2011.12.061
   PubMed Web of Science ®Google Scholar
• Chen S, Li J, Wang D, Fung H, Wong L-Y, Zhao L. The hepatitis B epidemic in China should receive more attention. Lancet. 2018;391(10130):1572. doi:10.1016/S0140-6736(18)30499-9
   PubMed Web of Science ®Google Scholar
• Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–538. doi:10.1016/j.jhep.2006.05.013
   PubMed Web of Science ®Google Scholar
• Jaacks LM, Vandevijvere S, Pan A, McGowan CJ, Wallace C, Imamura F, Mozaffarian D, Swinburn B, Ezzati M. The obesity transition: stages of the global epidemic. Lancet Diabetes Endocrinol. 2019;7(3):231–240. doi:10.1016/S2213-8587(19)30026-9
   PubMed Web of Science ®Google Scholar
• Daas SI, Rizeq BR, Nasrallah GK. Adipose tissue dysfunction in cancer cachexia. J Cell Physiol. 2018;234(1):13–22. doi:10.1002/jcp.26811
   PubMed Web of Science ®Google Scholar
• Tsoli M, Swarbrick MM, Robertson GR. Lipolytic and thermogenic depletion of adipose tissue in cancer cachexia. Semin Cell Dev Biol. 2016;54:68–81. doi:10.1016/j.semcdb.2015.10.039
   PubMed Web of Science ®Google Scholar
• Lopes HF, Correa-Giannella ML, Consolim-Colombo FM, Egan BM. Visceral adiposity syndrome. Diabetol Metab Syndr. 2016;8:40. doi:10.1186/s13098-016-0156-2
   PubMed Web of Science ®Google Scholar
• Snijder MB, Visser M, Dekker JM, Goodpaster BH, Harris TB, Kritchevsky SB, De Rekeneire N, Kanaya AM, Newman AB, Tylavsky FA, Health ABC Study, et al. Low subcutaneous thigh fat is a risk factor for unfavourable glucose and lipid levels, independently of high abdominal fat. The Health ABC Study. Diabetologia. 2005;48(2):301–308. doi:10.1007/s00125-004-1637-7
   PubMed Web of Science ®Google Scholar
• Parker R, Kim SJ, Gao B. Alcohol, adipose tissue and liver disease: mechanistic links and clinical considerations. Nat Rev Gastroenterol Hepatol. 2018;15(1):50–59. doi:10.1038/nrgastro.2017.116
   PubMed Web of Science ®Google Scholar
• Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu C-Y, Vasan RS, Murabito JM, Meigs JB, Cupples LA, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116(1):39–48. doi:10.1161/CIRCULATIONAHA.106.675355
   PubMed Web of Science ®Google Scholar
• Porter SA, Massaro JM, Hoffmann U, Vasan RS, O’Donnel CJ, Fox CS. Abdominal subcutaneous adipose tissue: a protective fat depot? Diabetes Care. 2009;32(6):1068–1075. doi:10.2337/dc08-2280
   PubMed Web of Science ®Google Scholar
• Tran TT, Yamamoto Y, Gesta S, Kahn CR. Beneficial effects of subcutaneous fat transplantation on metabolism. Cell Metab. 2008;7(5):410–420. doi:10.1016/j.cmet.2008.04.004
   PubMed Web of Science ®Google Scholar
• Kim NH, Jung YS, Park JH, Park DI, Sohn CI. Influence of obesity and metabolic abnormalities on the risk of developing colorectal neoplasia. Dig Dis Sci. 2018;63(11):3126–3133. doi:10.1007/s10620-018-5239-5
   PubMed Web of Science ®Google Scholar
• Ebadi M, Tandon P, Moctezuma-Velazquez C, Ghosh S, Baracos VE, Mazurak VC, Montano-Loza AJ. Low subcutaneous adiposity associates with higher mortality in female patients with cirrhosis. J Hepatol. 2018;69(3):608–616. doi:10.1016/j.jhep.2018.04.015
   PubMed Web of Science ®Google Scholar
• Dijksterhuis WPM, Pruijt MJ, van der Woude SO, Klaassen R, Kurk SA, van Oijen MGH, van Laarhoven HWM. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy. J Cachexia Sarcopenia Muscle. 2019;10(1):199–206. doi:10.1002/jcsm.12371
   PubMed Web of Science ®Google Scholar
• Nault J-C, Pigneur F, Nelson AC, Costentin C, Tselikas L, Katsahian S, Diao G, Laurent A, Mallat A, Duvoux C, et al. Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors. Dig Liver Dis. 2015;47(10):869–876. doi:10.1016/j.dld.2015.07.001
   PubMedGoogle Scholar
• Lee J, Cho Y, Park S, Kim JW, Lee IJ. Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with radiotherapy. Front Oncol. 2019;9:1075. doi:10.3389/fonc.2019.01075
   PubMed Web of Science ®Google Scholar